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Purpose

Methods

Implications for Practice

To compare long-acting injectables (LAIs) to oral
medications for treatment adherence in patients with
schizophrenia.

Eligibility Criteria
Ø Articles in the scoping review must contain the following:
• Evaluation of medication adherence
• Participants must have a diagnosis of schizophrenia and be taking a
long-acting injectable antipsychotic
• Patient population 18 years and older
• Retrieve all evidence from a peer-reviewed resource between 2000 to
2021
• Articles in English only

Ø Long term injectables improve patient outcomes in
schizophrenia

Objective
Ø PICOT Question
• In adult patients diagnosed with
schizophrenia (P), how do long-acting
injectables (I) compared to oral medications
(C) affect treatment adherence (O) over a
six-month period (T)?

Information Sources
Ø PubMed
Ø CINAHL
Search Strategy
Ø Initial Search Strategy
• Search terms
• "Adults schizophrenia and long-acting injectables and oral
medication and adherence and 6 months"
• Only 30 results on PubMed
Ø Revised Search Strategy
• Search terms
• "Adherence long-acting injectable schizophrenia"
• 431 results on PubMed
• Repeat same strategy with CINAHL Complete
Selection of Evidence
Ø Each contributor selects a minimum of five articles for review
Ø Rapid critical appraisal (RCA) of each article
Data Charting Process
Ø Synthesis and Outcomes Table
Ø Observable treatment outcomes
• Treatment adherence, rehospitalization, hospitalizations, risk of
discontinuation

Background
Ø Medication non-adherence with schizophrenia
• 40-60% of patients with schizophrenia are non-compliant
with oral antipsychotic medications
Ø Benefits of Long-acting injectables
• Treatment frequency of LAIs can range from every 2
weeks to every 3 months
• Can address treatment non-adherence
• Can be a replacement for oral antipsychotics
Ø Barriers to initiating treatment with LAIs
• Clinicians are reluctant to offer long-acting injectable
antipsychotics as a treatment choice

Ø Benefits have shown in the following:
• Medication compliance
• Hospitalization rate
• Recovery oriented goals (criminal behavior, spirituality)
• Rehospitalization and relapse rates

More research is needed to expand the
knowledge base
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Results
Variables measured

Hospitalization

(AOR=0.59, 95% CI=0.38-0.90, P=0.015).

Medication compliance

(t80=5.3; P<.001)

Recovery-oriented goals

Criminal behavior z=2.39, p=0.17, Spirituality z=2.20, p -.028

Ø Long term injectables were shown to be beneficial in treatment

adherence in schizophrenia
Ø Improvements noted in the following areas:
• Medication compliance
• Hospitalization
• Recovery oriented goals (criminal behavior, spirituality)
• Rehospitalization and relapse rate
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